Cross-presentation by dendritic cells

Nature Reviews Immunology

Volumn 12, Issue 8, 2012, Pages 557-569

  Joffre, Olivier P ^a,b   Segura, Elodie ^a,b   Savina, Ariel ^a,b   Amigorena, Sebastian ^a,b  

^a PSL RESEARCH UNIVERSITY   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CHLOROQUINE; DENDRITIC CELL VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; REACTIVE OXYGEN METABOLITE;

AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELL VACUOLE; CROSS PRESENTATION; CROSS TOLERANCE; CYTOSOL; DENDRITIC CELL; DRUG TARGETING; ENDOCYTOSIS; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VIVO STUDY; INFLUENZA; LUNG INFECTION; MALARIA; NONHUMAN; PHAGOCYTOSIS; PHAGOSOME; PLASMODIUM BERGHEI INFECTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; REVIEW; SKIN INFECTION; SPOROZOITE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE TOLERANCE; MICE;

EID: 84864332935     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3254     Document Type: Review

References (190)

1. Jung, S. et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17, 211-220 (2002). (Pubitemid 35245963)
2. Kovacsovics-Bankowski, M. & Rock, K. L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267, 243-246 (1995).
3. Houde, M. et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 425, 402-406 (2003). (Pubitemid 37187269)
4. Guermonprez, P. et al. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425, 397-402 (2003). (Pubitemid 37187268)
5. Burgdorf, S., Scholz, C., Kautz, A., Tampe, R. & Kurts, C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nature Immunol. 9, 558-566 (2008). (Pubitemid 351560525)
6. Firat, E. et al. The role of endoplasmic reticulum-associated aminopeptidase 1 in immunity to infection and in cross-presentation. J. Immunol. 178, 2241-2248 (2007). (Pubitemid 46233422)
7. Saveanu, L. et al. IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science 325, 213-217 (2009).
8. Shen, L., Sigal, L. J., Boes, M. & Rock, K. L. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 21, 155-165 (2004). (Pubitemid 39094046)
9. + T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. J. Immunol. 177, 3525-3533 (2006). (Pubitemid 44359883)
10. Merzougui, N., Kratzer, R., Saveanu, L. & van Endert, P. A proteasome-dependent, TAP-independent pathway for cross-presentation of phagocytosed antigen. EMBO Rep. 12, 1257-1264 (2011).
11. -/- macrophages are deficient in vacuolar alternate class I MHC (MHC-I) processing due to decreased MHC-I stability at phagolysosomal pH. J. Immunol. 170, 5825-5833 (2003). (Pubitemid 36682560)
12. + T cells. Cell 71, 1205-1214 (1992). (Pubitemid 23016554)
13. Day, P. M., Esquivel, F., Lukszo, J., Bennink, J. R. & Yewdell, J. W. Effect of TAP on the generation and intracellular trafficking of peptide-receptive major histocompatibility complex class I molecules. Immunity 2, 137-147 (1995).
14. Palmowski, M. J. et al. Role of immunoproteasomes in cross-presentation. J. Immunol. 177, 983-990 (2006). (Pubitemid 44036600)
15. Lizee, G. et al. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nature Immunol. 4, 1065-1073 (2003). (Pubitemid 37428034)
16. Basha, G. et al. A CD74-dependent MHC class I endolysosomal cross-presentation pathway. Nature Immunol. 13, 237-245 (2012).
17. Zou, L. et al. The GTPase RAB3B/3c-positive recycling vesicles are involved in cross-presentation in dendritic cells. Proc. Natl Acad. Sci. USA 106, 15801-15806 (2009).
18. Delamarre, L., Pack, M., Chang, H., Mellman, I. & Trombetta, E. S. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307, 1630-1634 (2005). (Pubitemid 40354746)
19. + T cell responses against soluble antigens in vivo. J. Exp. Med. 202, 817-828 (2005). (Pubitemid 41345970)
20. Belizaire, R. & Unanue, E. R. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc. Natl Acad. Sci. USA 106, 17463-17468 (2009).
21. Burgdorf, S., Kautz, A., Bohnert, V., Knolle, P. A. & Kurts, C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316, 612-616 (2007). (Pubitemid 46683149)
22. Tacken, P. J. et al. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 118, 4111-4119 (2011).
23. van Montfoort, N. et al. Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc. Natl Acad. Sci. USA 106, 6730-6735 (2009).
24. Savina, A. et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 126, 205-218 (2006). (Pubitemid 44026552)
25. Jancic, C. et al. RAB27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nature Cell Biol. 9, 367-378 (2007). (Pubitemid 46511070)
26. Mantegazza, A. R. et al. NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. Blood 112, 4712-4722 (2008).
27. Rybicka, J. M., Balce, D. R., Khan, M. F., Krohn, R. M. & Yates, R. M. NADPH oxidase activity controls phagosomal proteolysis in macrophages through modulation of the lumenal redox environment of phagosomes. Proc. Natl Acad. Sci. USA 107, 10496-10501 (2010).
28. Rybicka, J. M., Balce, D. R., Chaudhuri, S., Allan, E. R. & Yates, R. M. Phagosomal proteolysis in dendritic cells is modulated by NADPH oxidase in a pH-independent manner. EMBO J. 31, 932-944 (2012).
29. Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P. & Amigorena, S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nature Cell Biol. 1, 362-368 (1999). (Pubitemid 129493579)
30. Ackerman, A. L., Kyritsis, C., Tampe, R. & Cresswell, P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Natl Acad. Sci. USA 100, 12889-12894 (2003). (Pubitemid 37339995)
31. Gagnon, E. et al. Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. Cell 110, 119-131 (2002). (Pubitemid 34874611)
32. Muller-Taubenberger, A. et al. Calreticulin and calnexin in the endoplasmic reticulum are important for phagocytosis. EMBO J. 20, 6772-6782 (2001). (Pubitemid 33134207)
33. Touret, N. et al. Quantitative and dynamic assessment of the contribution of the ER to phagosome formation. Cell 123, 157-170 (2005). (Pubitemid 41414536)
34. Ackerman, A. L., Giodini, A. & Cresswell, P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 25, 607-617 (2006). (Pubitemid 44529035)
35. Cebrian, I. et al. SEC22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells. Cell 147, 1355-1368 (2011).
36. Norbury, C. C., Chambers, B. J., Prescott, A. R., Ljunggren, H. G. & Watts, C. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur. J. Immunol. 27, 280-288 (1997). (Pubitemid 27046089)
37. + dendritic cells by cytochrome c injection shows functional heterogeneity within this subset. Proc. Natl Acad. Sci. USA 105, 3029-3034 (2008).
38. Zehner, M. et al. Mannose receptor polyubiquitination regulates endosomal recruitment of p97 and cytosolic antigen translocation for cross-presentation. Proc. Natl Acad. Sci. USA 108, 9933-9938 (2011).
39. Segura, E., Albiston, A. L., Wicks, I. P., Chai, S. Y. & Villadangos, J. A. Different cross-presentation pathways in steady-state and inflammatory dendritic cells. Proc. Natl Acad. Sci. USA 106, 20377-20381 (2009).
40. Wang, X. et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127, 803-815 (2006). (Pubitemid 44716255)
41. Giodini, A. & Cresswell, P. Hsp90-mediated cytosolic refolding of exogenous proteins internalized by dendritic cells. EMBO J. 27, 201-211 (2008).
42. Singh, R. & Cresswell, P. Defective cross-presentation of viral antigens in GILT-free mice. Science 328, 1394-1398 (2010).
43. Imai, T. et al. Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells. Proc. Natl Acad. Sci. USA 108, 16363-16368 (2011).
44. Smith, M. H., Ploegh, H. L. & Weissman, J. S. Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science 334, 1086-1090 (2011).
45. Shortman, K. & Liu, Y. J. Mouse and human dendritic cell subtypes. Nature Rev. Immunol. 2, 151-161 (2002). (Pubitemid 37336516)
46. Vremec, D. et al. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J. Exp. Med. 176, 47-58 (1992).
47. Poulin, L. F. et al. The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells. J. Exp. Med. 204, 3119-3131 (2007).
48. Bursch, L. S. et al. Identification of a novel population of langerin+ dendritic cells. J. Exp. Med. 204, 3147-3156 (2007).
49. Ginhoux, F. et al. Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state. J. Exp. Med. 204, 3133-3146 (2007).
50. + DCs. J. Exp. Med. 206, 3115-3130 (2009).
51. Leon, B., Lopez-Bravo, M. & Ardavin, C. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26, 519-531 (2007). (Pubitemid 46602998)
52. Luber, C. A. et al. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity 32, 279-289 (2010).
53. Segura, E. et al. Differential expression of pathogen-recognition molecules between dendritic cell subsets revealed by plasma membrane proteomic analysis. Mol. Immunol. 47, 1765-1773 (2010).
54. + dendritic cell subset. Immunol. Rev. 234, 18-31 (2010).
55. Kamphorst, A. O., Guermonprez, P., Dudziak, D. & Nussenzweig, M. C. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J. Immunol. 185, 3426-3435 (2010).
56. + and CD8-dendritic cells in vivo. J. Exp. Med. 196, 817-827 (2002).
57. + T cells. J. Immunol. 178, 6861-6866 (2007). (Pubitemid 46847411)
58. +CD11b-but not plasmacytoid dendritic cells. J. Exp. Med. 205, 1621-1634 (2008). (Pubitemid 351962026)
59. + dendritic cell subpopulations following pulmonary poxvirus infection. J. Virol. 84, 10191-10199 (2010).
60. + pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J. Exp. Med. 208, 1789-1797 (2011).
61. + dendritic cells. Nature Immunol. 10, 488-495 (2009).
62. + dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J. Exp. Med. 207, 189-206 (2010).
63. Wang, L. et al. Langerin expressing cells promote skin immune responses under defined conditions. J. Immunol. 180, 4722-4727 (2008).
64. Bursch, L. S., Rich, B. E. & Hogquist, K. A. Langerhans cells are not required for the CD8 T cell response to epidermal self-antigens. J. Immunol. 182, 4657-4664 (2009).
65. Igyarto, B. Z. et al. Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses. Immunity 35, 260-272 (2011).
66. Villadangos, J. A. & Young, L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 29, 352-361 (2008).
67. Mouries, J. et al. Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 112, 3713-3722 (2008).
68. +, T cells by plasmacytoid dendritic cells. J. Exp. Med. 204, 1923-1933 (2007). (Pubitemid 47236327)
69. Lee, H. K. et al. Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection. J. Exp. Med. 206, 359-370 (2009).
70. + T cell crosspriming in vivo. Immunity 24, 191-201 (2006). (Pubitemid 43214588)
71. Wakim, L. M., Waithman, J., van Rooijen, N., Heath, W. R. & Carbone, F. R. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 319, 198-202 (2008).
72. Aldridge, J. R. Jr et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc. Natl Acad. Sci. USA 106, 5306-5311 (2009).
73. + T cell responses to influenza. Nature Immunol. 11, 216-224 (2010).
74. + dendritic cells capable of inducing antiviral T cell responses. J. Immunol. 182, 4200-4207 (2009).
75. Sathe, P. et al. The acquisition of antigen cross-presentation function by newly formed dendritic cells. J. Immunol. 186, 5184-5192 (2011).
76. Dzionek, A. et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165, 6037-6046 (2000).
77. Lindstedt, M., Lundberg, K. & Borrebaeck, C. A. Gene family clustering identifies functionally associated subsets of human in vivo blood and tonsillar dendritic cells. J. Immunol. 175, 4839-4846 (2005). (Pubitemid 41456365)
78. McIlroy, D. et al. Investigation of human spleen dendritic cell phenotype and distribution reveals evidence of in vivo activation in a subset of organ donors. Blood 97, 3470-3477 (2001).
79. Segura, E. et al. Characterization of resident and migratory dendritic cells in human lymph nodes. J. Exp. Med. 209, 653-660 (2012).
80. + dermal dendritic cells. Immunity 29, 497-510 (2008).
81. Haniffa, M. et al. Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. J. Exp. Med. 206, 371-385 (2009).
82. + dendritic cells. J. Exp. Med. 207, 1273-1281 (2010).
83. + dendritic cells. J. Exp. Med. 207, 1283-1292 (2010).
84. + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207, 1247-1260 (2010).
85. + dendritic cells. J. Exp. Med. 207, 1261-1271 (2010).
86. Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R. & Germain, R. N. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6, 715-726 (1997). (Pubitemid 27305734)
87. + dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195, 1289-1302 (2002). (Pubitemid 34564331)
88. + dendritic cells is attributable to their ability to internalize dead cells. Immunology 107, 183-189 (2002). (Pubitemid 35279044)
89. + dendritic cells. J. Immunol. 166, 5327-5330 (2001). (Pubitemid 32374150)
90. + dendritic cells in cross-presentation is not dictated by antigen capture. Proc. Natl Acad. Sci. USA 103, 10729-10734 (2006). (Pubitemid 44078044)
91. + dendritic cells. Immunity 30, 544-555 (2009).
92. Dudziak, D. et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315, 107-111 (2007). (Pubitemid 46196991)
93. + T cells. Immunity 31, 823-833 (2009).
94. + conventional dendritic cells. J. Exp. Med. 207, 823-836 (2010).
95. + type. J. Immunol. 187, 4411-4415 (2011).
96. + T cells in the peripheral interfollicular region of lymph nodes. Nature Immunol. 9, 155-165 (2008).
97. + T cell response. PLoS Pathog. 6, e1000768 (2010).
98. + T cells and dendritic cells during infection with Toxoplasma gondii. PLoS Pathog. 5, e1000505 (2009).
99. + T-cell activation after viral infection. Nature 471, 629-632 (2011).
100. Thery, C., Ostrowski, M. & Segura, E. Membrane vesicles as conveyors of immune responses. Nature Rev. Immunol. 9, 581-593 (2009).
101. Allan, R. S. et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25, 153-162 (2006). (Pubitemid 44066832)
102. + dendritic cells but not by Langerhans cells. Science 301, 1925-1928 (2003). (Pubitemid 37229056)
103. Eidsmo, L. et al. Differential migration of epidermal and dermal dendritic cells during skin infection. J. Immunol. 182, 3165-3172 (2009).
104. Belz, G. T. et al. Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. Proc. Natl Acad. Sci. USA 101, 8670-8675 (2004). (Pubitemid 38745829)
105. Lukens, M. V., Kruijsen, D., Coenjaerts, F. E., Kimpen, J. L. & van Bleek, G. M. Respiratory syncytial virus-induced activation and migration of respiratory dendritic cells and subsequent antigen presentation in the lung-draining lymph node. J. Virol. 83, 7235-7243 (2009).
106. Wilson, N. S. et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nature Immunol. 7, 165-172 (2006). (Pubitemid 43135882)
107. + dendritic cells. Proc. Natl Acad. Sci. USA 105, 14509-14514 (2008).
108. Cockburn, I. A. et al. Dendritic cells and hepatocytes use distinct pathways to process protective antigen from Plasmodium in vivo. PLoS Pathog. 7, e1001318 (2011).
109. + dendritic cells in cytotoxic T cell immunity. Science 322, 1097-1100 (2008).
110. + dendritic cells are the critical source of interleukin-12 that controls acute infection by Toxoplasma gondii tachyzoites. Immunity 35, 249-259 (2011).
111. Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989-2003 (2011).
112. + dendritic cells. J. Exp. Med. 208, 2005-2016 (2011).
113. + dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J. Immunol. 186, 5142-5150 (2011).
114. Asano, K. et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 34, 85-95 (2011).
115. Bevan, M. J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143, 1283-1288 (1976).
116. Bevan, M. J. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J. Immunol. 117, 2233-2238 (1976). (Pubitemid 8009022)
117. + but not CD8-dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685-1696 (2000).
118. + T cells are a prominent component of the allogeneic T-cell repertoire after skin graft rejection in mice. Transplantation 71, 418-421 (2001). (Pubitemid 32175979)
119. He, C. & Heeger, P. S. CD8 T cells can reject major histocompatibility complex class I-deficient skin allografts. Am. J. Transplant. 4, 698-704 (2004). (Pubitemid 38637566)
120. Celli, S., Albert, M. L. & Bousso, P. Visualizing the innate and adaptive immune responses underlying allograft rejection by two-photon microscopy. Nature Med. 17, 744-749 (2011).
121. + T cells mediate graft rejection via a distinct effector pathway. Nature Immunol. 3, 844-851 (2002).
122. + T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nature Med. 8, 233-239 (2002). (Pubitemid 34250100)
123. Anderson, M. S. et al. Projection of an immunological self shadow within the thymus by the Aire protein. Science 298, 1395-1401 (2002). (Pubitemid 35346134)
124. Derbinski, J., Schulte, A., Kyewski, B. & Klein, L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nature Immunol. 2, 1032-1039 (2001). (Pubitemid 33069498)
125. Gallegos, A. M. & Bevan, M. J. Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J. Exp. Med. 200, 1039-1049 (2004). (Pubitemid 39431128)
126. Gray, D., Abramson, J., Benoist, C. & Mathis, D. Proliferative arrest and rapid turnover of thymic epithelial cells expressing Aire. J. Exp. Med. 204, 2521-2528 (2007). (Pubitemid 350044777)
127. Viret, C., Barlow, A. K. & Janeway, C. A. Jr. On the intrathymic intercellular transfer of self-determinants. Immunol. Today 20, 8-10 (1999). (Pubitemid 29136542)
128. Koble, C. & Kyewski, B. The thymic medulla: a unique microenvironment for intercellular self-antigen transfer. J. Exp. Med. 206, 1505-1513 (2009).
129. Bonasio, R. et al. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nature Immunol. 7, 1092-1100 (2006). (Pubitemid 44420654)
130. Klein, L., Roettinger, B. & Kyewski, B. Sampling of complementing self-antigen pools by thymic stromal cells maximizes the scope of central T cell tolerance. Eur. J. Immunol. 31, 2476-2486 (2001). (Pubitemid 32785367)
131. Fontenot, J. D. & Rudensky, A. Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nature Immunol. 6, 331-337 (2005). (Pubitemid 41716769)
132. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212, 8-27 (2006). (Pubitemid 44116697)
133. + regulatory T cells. Immunol. Rev. 212, 60-73 (2006). (Pubitemid 44116700)
134. + T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J. Exp. Med. 194, 707-717 (2001). (Pubitemid 32983008)
135. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J. Exp. Med. 186, 2057-2062 (1997). (Pubitemid 28013691)
136. Kurts, C. et al. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184, 923-930 (1996). (Pubitemid 26313550)
137. + dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196, 1099-1104 (2002). (Pubitemid 35231768)
138. Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779 (2001). (Pubitemid 32983013)
139. + T cell tolerance. J. Exp. Med. 196, 1627-1638 (2002). (Pubitemid 36026474)
140. Dresch, C., Edelmann, S. L., Marconi, P. & Brocker, T. Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. J. Immunol. 181, 4495-4506 (2008).
141. + T cell tolerance in vivo. Immunity 28, 521-532 (2008).
142. + dendritic cells mediate cross-tolerance toward intestinal antigens. Blood 106, 201-206 (2005). (Pubitemid 40967193)
143. + T-cell cross-tolerance by dendritic cells. Eur. J. Immunol. 39, 2325-2330 (2009).
144. Lukacs-Kornek, V. et al. The kidney-renal lymph node-system contributes to cross-tolerance against innocuous circulating antigen. J. Immunol. 180, 706-715 (2008).
145. + dendritic cells display unique functional properties that are conserved between mice and humans. J. Exp. Med. 205, 2139-2149 (2008).
146. Cohen, J. N. et al. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J. Exp. Med. 207, 681-688 (2010).
147. Gardner, J. M. et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 321, 843-847 (2008).
148. Fletcher, A. L. et al. Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J. Exp. Med. 207, 689-697 (2010).
149. Nichols, L. A. et al. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J. Immunol. 179, 993-1003 (2007).
150. Lee, J. W. et al. Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nature Immunol. 8, 181-190 (2007).
151. Fletcher, A. L., Malhotra, D. & Turley, S. J. Lymph node stroma broaden the peripheral tolerance paradigm. Trends Immunol. 32, 12-18 (2010).
152. Vambutas, A. et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 23, 5271-5280 (2005). (Pubitemid 41443433)
153. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
154. Melief, C. J. Cancer immunotherapy by dendritic cells. Immunity 29, 372-383 (2008).
155. Zwaveling, S. et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358 (2002). (Pubitemid 34686155)
156. Faure, F. et al. Long-lasting cross-presentation of tumor antigen in human DC. Eur. J. Immunol. 39, 380-390 (2009).
157. + T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo. Clin. Vaccine Immunol. 15, 1497-1504 (2008).
158. Belnoue, E. et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J. Immunol. 172, 2487-2495 (2004). (Pubitemid 38182399)
159. Roestenberg, M. et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468-477 (2009).
160. Sauerwein, R. W., Bijker, E. M. & Richie, T. L. Empowering malaria vaccination by drug administration. Curr. Opin. Immunol. 22, 367-373 (2010).
161. Tacken, P. J., de Vries, I. J., Torensma, R. & Figdor, C. G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature Rev. Immunol. 7, 790-802 (2007). (Pubitemid 47480309)
162. Tacken, P. J. et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 118, 6836-6844 (2011).
163. Herre, J. et al. Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages. Blood 104, 4038-4045 (2004). (Pubitemid 39620154)
164. Bonifaz, L. C. et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199, 815-824 (2004). (Pubitemid 38375201)
165. Caminschi, I. et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112, 3264-3273 (2008).
166. Sancho, D. et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 118, 2098-2110 (2008). (Pubitemid 351872329)
167. Idoyaga, J. et al. Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J. Immunol. 180, 3647-3650 (2008).
168. + T cell epitopes. J. Immunol. 156, 4697-4706 (1996). (Pubitemid 26174453)
169. + T cell epitope from lymphocytic choriomeningitis virus. Proc. Natl Acad. Sci. USA 94, 3314-3319 (1997). (Pubitemid 27157308)
170. Srivastava, P. Roles of heat-shock proteins in innate and adaptive immunity. Nature Rev. Immunol. 2, 185-194 (2002). (Pubitemid 37328765)
171. Vingert, B. et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur. J. Immunol. 36, 1124-1135 (2006).
172. Idoyaga, J. et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc. Natl Acad. Sci. USA 108, 2384-2389 (2011).
173. Castro, F. V. et al. CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur. J. Immunol. 38, 2263-2273 (2008).
174. Kratzer, R., Mauvais, F. X., Burgevin, A., Barilleau, E. & van Endert, P. Fusion proteins for versatile antigen targeting to cell surface receptors reveal differential capacity to prime immune responses. J. Immunol. 184, 6855-6864 (2010).
175. + dendritic cells and a subset of monocytes. J. Biol. Chem. 283, 16693-16701 (2008).
176. + T-cell compartment by antigen targeting to DNGR-1/CLEC9A. Eur. J. Immunol. 40, 1255-1265 (2010).
177. + myeloid dendritic cells. Blood 119, 2284-2292 (2012).
178. Hoeffel, G. et al. Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 27, 481-492 (2007). (Pubitemid 47418679)
179. Mittag, D. et al. Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status. J. Immunol. 186, 6207-6217 (2011).
180. Sancho, D. et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458, 899-903 (2009).
181. Di Pucchio, T. et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nature Immunol. 9, 551-557 (2008). (Pubitemid 351560524)
182. Batchelor, J. R., Welsh, K. I., Maynard, A. & Burgos, H. Failure of long surviving, passively enhanced kidney allografts to provoke T-dependent alloimmunity. I. Retransplantation of (AS X AUG)F1 kidneys into secondary AS recipients. J. Exp. Med. 150, 455-464 (1979). (Pubitemid 9250679)
183. Lechler, R. I. & Batchelor, J. R. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J. Exp. Med. 155, 31-41 (1982). (Pubitemid 12209811)
184. Matzinger, P. & Bevan, M. J. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? Cell. Immunol. 29, 1-5 (1977). (Pubitemid 8070904)
185. Kaye, J. & Janeway, C. A. Jr. The Fab fragment of a directly activating monoclonal antibody that precipitates a disulfide-linked heterodimer from a helper T cell clone blocks activation by either allogeneic Ia or antigen and self-Ia. J. Exp. Med. 159, 1397-1412 (1984). (Pubitemid 14106457)
186. Smith, P. A., Brunmark, A., Jackson, M. R. & Potter, T. A. Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J. Exp. Med. 185, 1023-1033 (1997). (Pubitemid 27136795)
187. Jankovic, V., Remus, K., Molano, A. & Nikolich-Zugich, J. T cell recognition of an engineered MHC class I molecule: implications for peptide-independent alloreactivity. J. Immunol. 169, 1887-1892 (2002). (Pubitemid 34857651)
188. Obst, R., Netuschil, N., Klopfer, K., Stevanovic, S. & Rammensee, H. G. The role of peptides in T cell alloreactivity is determined by self-major histocompatibility complex molecules. J. Exp. Med. 191, 805-812 (2000).
189. Reiser, J. B. et al. Crystal structure of a T cell receptor bound to an allogeneic MHC molecule. Nature Immunol. 1, 291-297 (2000).
190. Luz, J. G. et al. Structural comparison of allogeneic and syngeneic T cell receptor-peptide-major histocompatibility complex complexes: a buried alloreactive mutation subtly alters peptide presentation substantially increasing Vβ interactions. J. Exp. Med. 195, 1175-1186 (2002). (Pubitemid 34517143)